Are Analysts Bearish Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) After Last Week?

June 18, 2018 - By Vivian Currie

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) LogoInvestors sentiment decreased to 0.86 in 2018 Q1. Its down 0.36, from 1.22 in 2017Q4. It is negative, as 23 investors sold Synergy Pharmaceuticals Inc. shares while 36 reduced holdings. 21 funds opened positions while 30 raised stakes. 104.06 million shares or 17.18% less from 125.65 million shares in 2017Q4 were reported.
10,457 are owned by Paloma Prns Mgmt Comm. Tower (Trc) holds 2,509 shares or 0% of its portfolio. Truepoint Inc has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 37 shares. Verition Fund Mngmt Llc has 13,729 shares. Northern Tru has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Brown Advisory has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Daiwa Securities stated it has 1,363 shares or 0% of all its holdings. Parallax Volatility Advisers L P has 10,475 shares. Schwab Charles Investment Mgmt holds 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) or 1.22M shares. 46,232 are held by Jane Street Group Inc Limited. Fny Managed Accounts Lc reported 1,000 shares. The New York-based Virtu Financial Ltd Liability Corp has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Credit Suisse Ag invested in 296,444 shares or 0% of the stock. Amalgamated Bank & Trust owns 33,000 shares. Hbk Sorce Advisory Llc reported 45,185 shares.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Ratings Coverage

Among 5 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Synergy Pharmaceuticals had 14 analyst reports since January 5, 2018 according to SRatingsIntel. On Friday, January 26 the stock rating was maintained by BTIG Research with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, February 1 report. The rating was maintained by Canaccord Genuity on Friday, May 11 with “Buy”. The firm has “Perform” rating given on Friday, January 5 by Oppenheimer. The firm has “Buy” rating given on Tuesday, March 6 by Cantor Fitzgerald. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by Cantor Fitzgerald on Thursday, January 25. On Monday, January 8 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Monday, May 14, the company rating was maintained by BTIG Research. The rating was maintained by H.C. Wainwright with “Buy” on Monday, May 7. Canaccord Genuity maintained it with “Buy” rating and $13.0 target in Thursday, January 25 report. Below is a list of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) latest ratings and price target changes.

06/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
14/05/2018 Broker: BTIG Research Rating: Buy New Target: $7.0000 Maintain
13/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $6.0000 Maintain
11/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $13.0000 Maintain
07/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
06/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $8.0 Maintain
05/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0 Maintain
25/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $13.0 Maintain
26/01/2018 Broker: BTIG Research Rating: Buy New Target: $7.0 Maintain

The stock decreased 0.55% or $0.01 during the last trading session, reaching $1.8. About 2.30M shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has declined 55.83% since June 18, 2017 and is downtrending. It has underperformed by 68.40% the S&P500.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. The company has market cap of $444.13 million. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. It currently has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

More news for Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) were recently published by: Streetinsider.com, which released: “Synergy Pharma (SGYP) Reports Amendment to CRG Debt Agreement” on June 13, 2018. Seekingalpha.com‘s article titled: “Synergy Pharma: Is Management Really That Bad?” and published on May 31, 2018 is yet another important article.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: